Isofol Medical
Isofol Medical AB is a Swedish biotechnology company focused on the development of arfolitixorin, a drug candidate aimed at improving treatment outcomes for metastatic colorectal cancer. The company is engaged in clinical trials and collaborates with international partners to expand its geographic reach. Isofol's primary goal is to address unmet medical needs in oncology through innovative first-line treatment options. The company operates from its headquarters in Gothenburg, Sweden, and leverages partnerships to enhance its research and development efforts globally.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueIncludes the development and clinical trials of arfolitixorin.
Customers
Isofol Medical's primary customers are pharmaceutical companies and healthcare providers involved in oncology. These entities are interested in Isofol's innovative treatment options for metastatic colorectal cancer. The company also collaborates with research institutions and hospitals for clinical trials. Isofol's strategic partnerships with international firms help in the commercialization and distribution of its drug candidates. The focus on first-line treatment solutions makes Isofol's offerings attractive to entities looking to enhance their oncology portfolios.
Interested in licensing and commercializing arfolitixorin for oncology.
Use Isofol's treatments for improving cancer patient outcomes.
Collaborate on clinical trials and research studies.
Strategy
Isofol Medical's strategic priorities include advancing the clinical development of arfolitixorin and expanding its geographic presence through strategic partnerships. The company is focused on securing regulatory approvals and patent protections to enhance its market position. Engaging with the scientific community through conferences and publications is key to Isofol's strategy to build credibility and interest in its drug candidate. The company aims to address unmet needs in oncology by integrating arfolitixorin into standard treatment protocols.
To establish efficacy and secure regulatory approvals.
To access new markets and increase drug availability.
Geography
Isofol Medical is headquartered in Gothenburg, Sweden, and has a significant presence in Europe. The company is expanding its geographic reach through partnerships in Japan, Canada, and the United States. These markets are key due to the high demand for innovative cancer treatments. Isofol actively participates in international oncology conferences, which enhances its visibility and strategic positioning globally. The company's geographic strategy is focused on leveraging partnerships to enter new markets and expand its clinical trial footprint.
Risks
Isofol Medical faces significant risks associated with the development of its sole drug candidate, arfolitixorin. The capital-intensive nature of drug development and the need for continuous financial and clinical resources pose substantial risks. Regulatory hurdles and the competitive landscape in oncology further add to the uncertainty. The company's reliance on partnerships for commercialization and geographic expansion introduces additional risks related to partner performance and market acceptance. Isofol actively manages these risks through ongoing evaluations and strategic planning.
- Capital-intensive drug developmentImpact: CriticalLikelihood: High
Requires significant financial resources for clinical trials.
- Regulatory approval challengesImpact: HighLikelihood: Medium
Potential delays or denials can impact market entry.
Accounting
Judgemental itemsNo sales revenue, affects financial stability and planning.
Impact: high
Similar listed companies
Publicly listed companies with a comparable business focus.
Swedish Orphan Biovitrum
SOBI · Health Care
Swedish Orphan Biovitrum AB (Sobi) is a global biopharmaceutical company dedicated to transforming the lives of individuals with rare and debilitating diseases.
Ascelia Pharma
ACE · Health Care
Ascelia Pharma is a Swedish pharmaceutical company headquartered in Malmö, with a US base in New Jersey.
Vicore Pharma Holding AB
VCRE · Pharmaceutical Preparations
Vicore Pharma Holding AB is a Swedish pharmaceutical development company focused on research and development of drug candidates for severe respiratory and fibrotic diseases.
Bolt Biotherapeutics, Inc.
BOLT · Pharmaceutical Preparations
BioArctic
BIOA-B · Health Care
BioArctic AB is a Swedish biopharmaceutical company focused on developing innovative treatments for severe neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS.
Cantargia
CANTA · Health Care
Cantargia is a Swedish biotechnology company focused on developing targeted antibody-based drugs for cancer, immunological, and other life-threatening diseases.
Last updated: 24/09/2026